Although kits to detect cryptococcal antigen are used widely to diagnose cryptococcal infection, the comparative performance of commercially available assays has not been evaluated in the past decade. Therefore, we compared the sensitivities and specificities of five commercially available kits for detecting For CSF specimens, the sensitivities and specificities of all kits were comparable (sensitivity, 93 to 100%; specificity, 93 to 98%). There was a significant difference in sensitivities of the kits when serum samples were tested with the International Biological Labs and MicroScan kits, which do not pretreat serum with pronase. These kits were less sensitive (sensitivity, 83%) than the Immy and Meridian latex kits (sensitivity, 97%), which do pretreat with pronase. The sensitivity of the Meridian enzyme immunoassay kit was comparable to that of the pronase-containing latex kits. These kits were of equivalent specificities (93 to 100%) when testing serum. Some of the currently available kits have limitations that need to be recognized for proper interpretation of results. Specifically, the use of pronase on serum samples reduces the number of false-positive results, and a titer of <1:4 can be a false-positive result when CSF samples are being tested.
Cryptococcal meningitis has become increasingly prevalent during the AIDS epidemic, affecting approximately 10% of patients with this syndrome (15) . In view of the increasing number of infections, rapid, sensitive, and specific diagnosis of cryptococcal disease has become more important than ever. The detection of cryptococcal capsular antigen in serum and cerebrospinal fluid (CSF) by latex agglutination is rapid and has been documented to be both sensitive and specific (8, 19) . There are currently four commercially available latex cryptococcal antigen tests (LCATs) as well as a new enzyme-linked immunoassay (EIA) test to detect cryptococcal capsular antigen. Although detection of cryptococcal antigen in serum and CSF has come to be relied upon in the diagnosis and management of cryptococcosis, there have been no direct comparisons of all commercially available kits. Therefore, we compared the five kits versus cultures to determine their sensitivities and specificities in diagnosing cryptococcal disease. In addition, we compared titers obtained with each of the cryptococcal antigen kits (7, 16, 17) , since titration of antigen in serum and CSF has been used to determine prognosis and to evaluate response to therapy, despite use of different kits at different clinical sites in some of the multicenter therapeutic trials.
MATERIALS AND METHODS
Kits. We evaluated the Crypto-LA (International Biological Labs, Inc., Cranbury, N.J.) (IBL), Myco-Immune (American MicroScan, Mahwah, N.J.), Immy Latex-Crypto Antigen (Im-muno-Mycologics, Inc., Norman, Okla.), and Calas (Meridian Diagnostics, Inc., Cincinnati, Ohio) LCATs, as well as the Meridian Premier EIA for detection of cryptococcal antigen in serum and CSF. All kits were used according to manufacturers' instructions. The latex kits all required heat inactivation to reduce nonspecific interference and inactivate complement. Three kits provided a normal globulin control to detect nonspecific interference; the Immy kit did not. Two kits, the Immy kit on serum and CSF and the Meridian LCAT on serum only, also used pronase to further limit nonspecific interference. The EIA kit required no specimen preparation beyond centrifugation.
Guidelines for interpretation of LCAT results varied by manufacturer, with all relying on a subjective interpretation by the observer. The EIA titers were calculated with A450 values (absorbance x dilution factor x control factor). Some of the pertinent differences in specimen preparation and result interpretation are listed by manufacturer in Table 1 Sensitivity and specificity for CSF samples. The sensitivities and specificities of the kits were excellent, as indicated in Table  2 . Of the 19 true-positive CSF samples, 100% were detected by the IBL, MicroScan, and Meridian LCAT and EIA. The Immy LCAT failed to detect one culture-positive sample that was positive at a low titer (1:2, 1:2, and 1:8 with the IBL, MicroScan, and Meridian LCATs, respectively). The false-positive rate was low for all kits tested: 3, 3, 7, and 4% for the IBL, MicroScan, Immy, and Meridian LCATs, respectively, and 2% for the Meridian EIA. The majority of the false-positive results had titers of less than or equal to 1:4. The number of false-positive tests was highest with the Immy kit. Of these, half were at a titer of 1:1, and all true positives detected with this kit had a titer of greater than or equal to 1:8.
Only 5 of a total of 28 false-positive tests with the four LCAT kits had titers of 1:8 or greater. Of these five false positives, four represented one specimen that was positive by all four LCAT kits with titers of 1:8 to 1:16 but negative by the EIA kit and culture. This patient's serum cryptococcal antigen was negative with all five kits, and a follow-up at 18 months has revealed no evidence of cryptococcal disease. One other patient's CSF was positive by all four LCATs at a titer of 1:4 but also was negative by EIA and culture. Serum cryptococcal antigen was negative, and a follow-up 1 year later has revealed no evidence of cryptococcal infection.
There were three false-positive results by EIA. Two were negative by all four LCAT kits and culture of CSF. A third patient with a positive EIA titer of 1:1 did have a positive urine culture for C. neofornans with multiple negative CSF cultures. This patient was treated with fluconazole but developed positive serum cryptococcal antigen by all five kits at high titers 1 month later. There was no other evidence of cryptococcal meningitis. There were two samples from different patients that gave indeterminate readings by EIA. One sample was repeatedly indeterminate; testing of the other was not repeated because of inadequate sample volume.
Sensitivity and specificity for serum samples. The sensitivities and specificities of the kits were good to excellent when serum samples were tested ( Table 2) . Of the 30 true-positive serum samples, only 83% were detected by the IBL and MicroScan kits compared with 97% for the Immy and Meridian LCAT kits. The Meridian EIA had a sensitivity of 93%. Specificity was high for all kits, although the IBL and MicroScan kits were slightly better than the Meridian and Immy kits. The false-positive rate was low for all the kits tested: 1, 0, 5, and 3% for the IBL, MicroScan, Immy, and Meridian LCATs, respectively, and 2% for the Meridian EIA. As with the CSF samples, the number of false positives was highest with the Immy kit. Three of four false-positive results were at a titer of 1:1, whereas all of the true-positive results with this kit were at a titer of greater than or equal to 1:32.
All except one of the false-positive tests with the four LCAT Table 3 .
The two false-negative tests with the Meridian EIA also were negative by the IBL and MicroScan LCAT kits. Both patients were rheumatoid factor negative. Unfortunately, the specimen volume was insufficient to repeat the EIA after pronase treatment.
Titers. There were substantial variations in titers among LCAT kits for samples whose end point titers were determined. The MicroScan assay consistently had the highest titers, and the Meridian LCAT had the lowest on both CSF and serum. The geometric means for serum and CSF titers are shown by kit in Table 4 .
The end point titers of 20 serum samples were compared among LCAT kits. The Meridian LCAT was chosen as the reference kit because, overall, it was the most sensitive and specific kit (Table 2 ). There was agreement (± 1 twofold dilution) among the Meridian and the IBL, MicroScan, and Immy LCATs 60, 30, and 55% of the time, respectively. The IBL and MicroScan kits ranged from 6 dilutions less to 5 dilutions greater than the Meridian LCAT. The range for the Immy LCAT was from 3 dilutions less to 8 dilutions greater than the Meridian LCAT. Twenty percent of the titers with the IBL LCAT were more than 1 dilution greater than the titers with the Meridian LCAT, and 20% were more than 1 dilution less than the Meridian LCAT titers. Thirty-five percent of the MicroScan titers were more than 1 dilution greater, and 35% were more than 1 dilution less than the Meridian titers. Ten agreement that the titer was high by the three other LCAT kits. Eight of 30 (27%) true-positive samples by the Meridian LCAT had low titers. The other three LCAT kits agreed that the titer was low 48% of the time.
The Meridian EIA kit titers roughly paralleled the LCAT kits (i.e., high titers by LCAT were also high by EIA). However, the values obtained by EIA were always higher than the LCAT values, although the correlation was not linear. DISCUSSION This is the first systematic comparison of all commercially available kits for detection of cryptococcal antigen since 1983 (19) and the first during the AIDS epidemic. There were three LCAT kits compared in 1983: IBL, MicroScan (formerly marketed by American Scientific Products), and Immy. In that study (19) , the IBL kit had a sensitivity and specificity of 100% for both serum and CSF, the MicroScan had a sensitivity of 100% for both serum and CSF and specificities of 99% for serum and 100% for CSF, and the Immy had sensitivities of 45% for serum and 83% for CSF and a specificity of 100% for both serum and CSF. On the basis of the methodologies used in 1983 (19) , there have been substantive changes to the Immy kit since 1983, including the addition of pronase treatment. Our data show that both its sensitivity and its specificity have improved significantly. Moreover, 6 of 12 and 3 of 4 Immy false positives from serum and CSF, respectively, could have been eliminated if the threshold for a positive result had been defined as a titer of 1:2 or greater rather than 1:1. This interpretive revision would have further improved specificity and not reduced sensitivity at all.
Perhaps most notable among the LCAT kits were the differences in sensitivities of these kits in detecting cryptococcal antigen in serum. In our study the sensitivity of those kits that included pronase treatment of serum was remarkably higher than the sensitivity of those that did not (97 versus 83%). Among those kits that did not use pronase, we found a 6% false-negative rate and, in the two samples we were able to test, demonstrated that these could be eliminated by pronase treatment. This false-negative rate is lower than the 19 and 27% rates reported by Gray and Roberts (11) and Hamilton et al. (12) , respectively. The value of pronase in eliminating false negatives for serum samples has been demonstrated previously (11, 12 (9, 14, 17) . Some have provided no data as to which kits were used and, nevertheless, drawn conclusions pertaining to clinical outcomes based on titers (1-4, 13, 18, 20) . Others In general, the LCAT kits should be viewed as equivalent in diagnosing cryptococcal disease in CSF. However, the Meridian and Immy are superior to the IBL and MicroScan for serum because they include pronase. The Meridian LCAT appears to be the most sensitive and specific kit overall. All kits were easy to use, although end point determination was easiest with the Meridian LCAT kit.
The Meridian EIA kit was as sensitive and specific as the best LCAT kit. The most significant problem we encountered concerned two kits that included controls that were repeatedly out of range. This problem is being remedied by the manufacturer (lOa). As with most EIA kits, this kit is best used with fairly large numbers of samples that can be batched. We found that a washer was useful for infection control purposes, allowing us to deal with human immunodeficiency viruspositive body fluids without risk of splashing. As shown by Gade et al. (10) , titers with the EIA are calculated and bear no numerical relation to LCAT titers (10) . However, in general, high titers by EIA were also high by LCAT.
